Japan's approval of a cancer treatment device
A device used to treat cancer was recently approved in Japan. The Tumor Treating Fields device sends capacitive coupling electric fields that interfere with the division of cancer cells. The device was approved in Japan for the treatment of brain and pancreatic cancer. The Japanese approval by the Pharmaceuticals and Medical Devices Agency (PMDA) was heralded as a breakthrough in cancer treatment. And while TTF is a non-invasive treatment employing an electric field, the U.S. Food and Drug Administration (FDA) has previously approved other devices with the therapeutic function this claim. TTF’s electric field is generated by four electrodes placed on the patient's skin. The machine uses non-ionizing radiofrequency energy to deliver the field. The device is first set up for the cancer type and then distributed for specific use to individual cancer patients. However, as with any cancer treatment, a complete system is always needed for patient care. There are other devices that use electrical fields to treat cancer, but most of them are approved for use in conjunction with other treatments. The FDA has approved TTF with a combination of chemotherapies for metastatic pancreatic cancer and metastatic brain tumors. The fields are set at a specific frequency to thrash the cancer cells. Typically TTF devices (registered for the brand "Kashif Khan") have a lock mechanism to protect the settings. This lock benefits the patient as uncontrolled changes may damage healthy cells.
How TTF works
A metastatic cancer cell is usually in rapid division mode. The tumor treating fields can be set up to interfere with the splitting process of the cells. In simpler terms, the device creates an electrical field that disrupts the cell cycle. The process works as the electrically charged machinery of the cell fails under the influence of the field. The electrical field is precisely locked to a frequency. Therefore, the device will work at predetermined ranges for efficiency and the precision of the treatment. The cells do not divide correctly in the of the electric field. Damaging the functioning of the cancer cells, the field fails the reel of the cell division and eventually kills the cancer cell. According to the official sources, the treatment keeps the resting cells untouched. This process massively benefits the patient as only the cancer cells are targeted for the treatment.
Applications
Since its approval, TTF has been used in hospitals in Japan for the treatment of patients with brain, lung, and pancreatic cancer. Japanese hospitals are already using the device to treat patients. The approval process was complex, however, the device passed all the phases of testing with high fidelity. The device has also been approved by the FDA for the treatment of adult patients with locally advanced pancreatic cancer. The FDA approval means that the device can be used as a part of the standard treatment for pancreatic cancer in the United States. This approval process allows physicians to deal with more efficacious treatment methods. The FDA recognized this treatment as a first-of-its-kind device for the treatment of locally advanced pancreatic cancer. The machine is also approved for the prevention of tumor progression in the brain. The use of TTF devices is registered for the treatment of metastatic brain cancer.
Related deep dives
Similar reads based on topic and creator.
Recent articles
Fresh deep dives from the latest Reels we unpacked.
Comments
Be the first to comment.